Comerica Bank
ALLO icon

Comerica Bank’s Allogene Therapeutics ALLO Stock Holding History

Comerica Bank’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,916
Closed -$5.37K – 3680
2024
Q3 		$5.37K Hold
1,916
– – ﹤0.01% 3309
2024
Q2 		$4.46K Buy
1,916
+1,302
+212% +$3.84K ﹤0.01% 3326
2024
Q1 		$2.75K Buy
+614
New +$2.56K ﹤0.01% 3472

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Comerica Bank's ALLO Position: Q4 2024 in Review

Comerica Bank sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 1,916 shares — an estimated $5.37K sold.

Comerica Bank first reported a position in ALLO in Q1 2024 and held it in 3 quarters. The position peaked at $5.37K in Q3 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

  • Comerica Bank reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Comerica Bank sold 1,916 Allogene Therapeutics shares in Q4 2024, an estimated $5.37K.
  • Comerica Bank first reported a position in Allogene Therapeutics in Q1 2024 and held it in 3 quarters.
  • Comerica Bank's Allogene Therapeutics position peaked at $5.37K in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on Comerica Bank's 13F filing for Q4 2024, filed 14 Feb 2025.